TrialReader


Effects of Continuous Dexmedetomidine Infusion on Systemic Microvascular Function in Laparoscopic Cholecystecthomy

NCT04946396 — Not applicable, Completed, 64 participants, National Institute of Cardiology, Laranjeiras, Brazil

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Evaluation of the Effects of Continuous Dexmedetomidine Infusion on Systemic Microvascular Function in Patients Undergoing Laparoscopic Cholecystecthomy: a Prospective Study

RegistryNCT04946396
StatusCompleted
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: quadruple, treatment
Enrollment64 (Actual)
SponsorNational Institute of Cardiology, Laranjeiras, Brazil (Other gov)
ConditionsLaparoscopic Surgery
Interventionsdexmedetomidine intravenous infusion, 0.9%sodium chloride (Drug)
Datesstart 2022-04-01, primary completion 2025-05-30, completion 2025-08-30, first posted 2021-06-30, last updated 2025-12-03
Locations1 site in Brazil

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Laparoscopic Surgery All trials of dexmedetomidine intravenous infusion All trials of 0.9%sodium chloride

-Summary

The microcirculation represents the primary site of exchange of oxygen and nutrients for tissues, and the preservation of microcirculatory perfusion is essential for the maintenance of organ function. The microcirculation is extremely dynamic and may vary according to the individual's temperature, systemic blood pressure, the use of medications, during physical and mental activity, age and pathological processes. In this context, the development of portable microscopes for clinical use has made possible the non-invasive visualization of the microcirculation and tissue perfusion in patients undergoing several highly complex procedures in cardiology, including cardiac surgery with cardiopulmonary bypass, ECMO (Extracorporeal Membrane Oxygenation) and in critically ill patients in intensive care.

CytoCam, for example, is a handheld device that incorporates a darkfield incident light illumination system with a series of high-resolution lenses that project images to a computer dedicated to the system. Dexmedetomidine is a selective agonist of 2-adrenergic receptors in the central nervous system, whose administration results in a reduction in the activity of the sympathetic nervous system and a reduction in the systemic release of catecholamines. Its use in the perioperative period has several beneficial effects, such as reducing neuroendocrine and hemodynamic responses due to anesthesia and surgery, through induction of sedation and analgesia, in addition to reducing the consumption of opioids and anesthetics in general. Several recent studies report that the use of dexmedetomidine in the perioperative period reduces the incidence of postoperative complications, reduces the time on mechanical ventilation and attenuates the neuroendocrine response due to surgical trauma and extracorporeal circulation in patients undergoing cardiac surgery. However, the effects of dexmedetomidine on systemic microcirculation function during its use in anesthesia for elective surgical procedures of medium complexity are not yet known. In conclusion, the hypothesis of the present study is that continuous intravenous infusion of dexmedetomidine during balanced general anesthesia increases the microvascular perfusion flow rate in the sublingual mucosa, representing an increase in systemic microvascular perfusion.

Expand all sections  ·  Collapse all

+Detailed description

CytoCam, is a handheld device that incorporates a darkfield incident light illumination system with a series of high-resolution lenses that project images to a computer dedicated to the system. Dexmedetomidine is a selective agonist of 2-adrenergic receptors in the central nervous system, whose administration results in a reduction in the activity of the sympathetic nervous system and a reduction in the systemic release of catecholamines. Its use in the perioperative period has several beneficial effects, such as reducing neuroendocrine and hemodynamic responses due to anesthesia and surgery, through induction of sedation and analgesia, in addition to reducing the consumption of opioids and anesthetics in general. Several recent studies report that the use of dexmedetomidine in the perioperative period reduces the incidence of postoperative complications, reduces the time on mechanical ventilation and attenuates the neuroendocrine response due to surgical trauma and extracorporeal circulation in patients undergoing cardiac surgery. However, the effects of dexmedetomidine on systemic microcirculation function during its use in anesthesia for elective surgical procedures of medium complexity are not yet known. In conclusion, the hypothesis of the present study is that continuous intravenous infusion of dexmedetomidine during balanced general anesthesia increases the microvascular perfusion flow rate in the sublingual mucosa, representing an increase in systemic microvascular perfusion.

+Arms and interventions

ArmTypeInterventionsDescription
dexmedetomidine intravenous infusionExperimentalDrug: dexmedetomidine intravenous infusionPatients who will receive continuous intraoperative infusion of dexmedetomidine hydrochloride (0.5 µg/kg/h).
0.9% saline solution intravenous infusionSham comparatorDrug: 0.9%sodium chloridePatients who will receive continuous infusion of 0.9% saline solution (sham group).
  • dexmedetomidine intravenous infusion (Drug): Dexmedetomidine intravenous infusion during laparoscopic cholecystecthomy
  • 0.9%sodium chloride (Drug): 0.9%sodium chloride intravenous infusion during laparoscopic cholecystecthomy

+Outcome measures

Primary outcomes

  • change in microvascular flow index [during surgery]: sublingual microvascular density

+Eligibility

Sex: All, ages: 18 Years to 60 Years

Inclusion Criteria:

* Adult patients of both sexes (age ≥ 18 and ≤ 60 years)
* Physical state ASA I or II according to the criteria of the American Association of Anesthesiology
* Planned surgery of cholecystectomy by videolaparoscopy

Exclusion Criteria:

* Patient's refusal to participate in the study
* Inflammation or infection in the sublingual mucosa
* Emergency surgery
* Grade III obesity (BMI ≥39.9 kg/m2)
* Pregnancy or lactation
* Autoimmune diseases, malignant neoplasms

+Locations (1)

FacilityCityCountryStatus
Eduardo TibiriçáRio de JaneiroBrazil

+Investigators

  • EDUARDO TIBIRICA, MD, PhD, Principal investigator, National Institute of Cardiology

My Notes